Answers are grounded in this paper and cite their sources.
Cross-sectional genetic study identifies links between statin use and erectile dysfunction in cardiac patients, suggesting genetic variants play a role.
Erectile dysfunction (ED) is a significant disorder commonly found in patients with cardiovascular diseases and diabetes mellitus. Recent updates have indicated that statins may also contribute to an increased risk of ED. This cross-sectional genetic study involved 246 cardiac patients attending normal visits at Hospital Universiti Sains Malaysia (USM) Kubang Kerian outpatient clinics. The patients were categorized into four groups: statins with ED (group 1), statins without ED (group 2), diabetes with statin without ED (group 3), and healthy patients without diabetes mellitus and statin use (group 4). Six genes were hypothesized to influence ED: CYP19A1, CYP17A1, SIM1, TP53, NR2F2, and NOS3, with different polymorphisms and variants investigated in this study. Overall, statin therapy was found to have a negative impact on ED by affecting NR2F2-AS1 and NOS3. However, atorvastatin showed varying effects on ED for all genes, with the highest impact observed with CYP17A1 and the lowest with CYP19A1. In conclusion, this study revealed novel findings related to genetic factors influencing ED in Malaysian males during statin use.
No takes yet. Share an insight, caveat, or question.
Adeeb et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: